DMAC
Price
$7.07
Change
+$0.07 (+1.00%)
Updated
Oct 3 closing price
Capitalization
361.82M
32 days until earnings call
HMTXF
Price
$0.07
Change
-$0.00 (-0.00%)
Updated
Oct 3 closing price
Capitalization
13.65M
Interact to see
Advertisement

DMAC vs HMTXF

Header iconDMAC vs HMTXF Comparison
Open Charts DMAC vs HMTXFBanner chart's image
DiaMedica Therapeutics
Price$7.07
Change+$0.07 (+1.00%)
Volume$229.51K
Capitalization361.82M
Hemostemix
Price$0.07
Change-$0.00 (-0.00%)
Volume$1.96K
Capitalization13.65M
DMAC vs HMTXF Comparison Chart in %
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HMTXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DMAC vs. HMTXF commentary
Oct 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a StrongBuy and HMTXF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 04, 2025
Stock price -- (DMAC: $7.07 vs. HMTXF: $0.07)
Brand notoriety: DMAC and HMTXF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 59% vs. HMTXF: 8%
Market capitalization -- DMAC: $361.82M vs. HMTXF: $13.65M
DMAC [@Biotechnology] is valued at $361.82M. HMTXF’s [@Biotechnology] market capitalization is $13.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $104.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 0 FA rating(s) are green whileHMTXF’s FA Score has 1 green FA rating(s).

  • DMAC’s FA Score: 0 green, 5 red.
  • HMTXF’s FA Score: 1 green, 4 red.
According to our system of comparison, HMTXF is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 5 TA indicator(s) are bullish while HMTXF’s TA Score has 5 bullish TA indicator(s).

  • DMAC’s TA Score: 5 bullish, 4 bearish.
  • HMTXF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both DMAC and HMTXF are a good buy in the short-term.

Price Growth

DMAC (@Biotechnology) experienced а +1.87% price change this week, while HMTXF (@Biotechnology) price change was +6.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DMAC($362M) has a higher market cap than HMTXF($13.7M). DMAC YTD gains are higher at: 30.203 vs. HMTXF (1.548). HMTXF has higher annual earnings (EBITDA): -2.48M vs. DMAC (-31.42M). DMAC has more cash in the bank: 30M vs. HMTXF (825K). DMAC has less debt than HMTXF: DMAC (292K) vs HMTXF (4.87M). DMAC (0) and HMTXF (0) have equivalent revenues.
DMACHMTXFDMAC / HMTXF
Capitalization362M13.7M2,642%
EBITDA-31.42M-2.48M1,268%
Gain YTD30.2031.5481,952%
P/E RatioN/AN/A-
Revenue00-
Total Cash30M825K3,636%
Total Debt292K4.87M6%
FUNDAMENTALS RATINGS
DMAC vs HMTXF: Fundamental Ratings
DMAC
HMTXF
OUTLOOK RATING
1..100
8026
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
75100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HMTXF's Valuation (4) in the null industry is somewhat better than the same rating for DMAC (68) in the Biotechnology industry. This means that HMTXF’s stock grew somewhat faster than DMAC’s over the last 12 months.

DMAC's Profit vs Risk Rating (75) in the Biotechnology industry is in the same range as HMTXF (100) in the null industry. This means that DMAC’s stock grew similarly to HMTXF’s over the last 12 months.

DMAC's SMR Rating (98) in the Biotechnology industry is in the same range as HMTXF (100) in the null industry. This means that DMAC’s stock grew similarly to HMTXF’s over the last 12 months.

DMAC's Price Growth Rating (37) in the Biotechnology industry is in the same range as HMTXF (65) in the null industry. This means that DMAC’s stock grew similarly to HMTXF’s over the last 12 months.

DMAC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as HMTXF (100) in the null industry. This means that DMAC’s stock grew similarly to HMTXF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMACHMTXF
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
66%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
70%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 20 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HMTXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RTNTF85.004.00
+4.94%
Rio Tinto Ltd.
IRCDF1.37N/A
N/A
Intercede Group PLC
ARSUF23.50N/A
N/A
Fagron SA
FOVSY12.69N/A
N/A
Ford Otomotiv Sanayi AS
SFES0.87-0.04
-3.88%
Safeguard Scientifics, Inc.

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+1.00%
WHWK - DMAC
44%
Loosely correlated
+1.03%
ARCT - DMAC
36%
Loosely correlated
+3.11%
HUMA - DMAC
33%
Poorly correlated
+17.32%
PRLD - DMAC
32%
Poorly correlated
+2.08%
EDIT - DMAC
31%
Poorly correlated
+0.77%
More

HMTXF and

Correlation & Price change

A.I.dvisor tells us that HMTXF and DMAC have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HMTXF and DMAC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HMTXF
1D Price
Change %
HMTXF100%
+6.43%
DMAC - HMTXF
22%
Poorly correlated
+1.00%
BIVI - HMTXF
21%
Poorly correlated
-2.50%
AGEN - HMTXF
21%
Poorly correlated
+5.08%
DVHGF - HMTXF
21%
Poorly correlated
N/A
FDMT - HMTXF
12%
Poorly correlated
-1.38%
More